Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Lilly's (LLY) products were taken off the shortage list in October. Some of Novo Nordisk's (NVO) semaglutide formulations remain on the list. Lilly (LLY) markets tirzepatide for diabetes as ...

The plant will be used to "support increased demand for existing Lilly products and play a key role in bringing Lilly's robust clinical pipeline…to patients around the world," said the IDA ...

Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday ...

Lilly is providing the low-dose vials solely through LillyDirect, in effect steering patients towards its products. Additionally, while patients can access medicines through LillyDirect prescribed ...

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

Minnesota Attorney General Keith Ellison announced on Monday that a settlement has been reached Novo Nordisk over the high ...

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...